Illumina PRS grant winner investigates genetic linkage between opioid use disorder and chronic pain

11 April 2024

Illumina congratulates Emma Johnson, PhD, Assistant Professor in Psychiatry at Washington University School of Medicine in St. Louis for winning the Illumina Polygenic Research Grant Contest. Professor Johnson and her colleagues, Arpana Agrawal, PhD, Professor of Psychiatry, and Simon Haroutounian, PhD, Chief of Clinical Research at the Washington University Pain Center, will use Illumina and Allelica technology to genotype at least 1000 surgery patients from an ongoing P5 study (PI: Dr. Haroutounian) to understand the transition from acute to chronic postoperative pain. Ultimately, this research aims to develop polygenic risk scores (PRS) for chronic pain and Opioid Use Disorder (OUD), enabling clinicians to one day more effectively manage and prevent post-surgical pain, as well as providing a resource for stratification of high-risk individuals who may develop OUD alongside chronic pain. Learn more about the PRS grant winning submission here: https://www.illumina.com/company/news-center/feature-articles/prs-grant-winner-2023.html M-GL-02756 For Research Use Only. Not for use in diagnostic procedures. © 2024 Illumina, Inc. All Rights Reserved. #polygenicriskscores #infinium #illumina Subscribe to the Illumina video channel http://www.youtube.com/subscription_center?add_user=IlluminaInc A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. View customer spotlight videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajfheLzgbI4S7xBn7IDbt79 View Illumina webinars https://www.youtube.com/playlist?list=PLKRu7cmBQlahpXlnrrXlQw9itVJ8yHwUZ View Illumina support videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvM Facebook: https://www.facebook.com/illuminainc LinkedIn: https://www.linkedin.com/company/illumina Instagram: https://www.instagram.com/illuminainc/ Twitter: https://twitter.com/illumina

Share this article on    
    
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see sapac.illumina.com/company/legal.html.

© 2024 Illumina, Inc. All rights reserved.